Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CRHBP | P24387 | 1/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406122 | 1.00 | MAPT (0.30) | MAPTCRHBPCRHR2FAAHPTGS1 | |
| SCHEMBL3402840 | 1.00 | MAPT (0.30) | MAPTCRHBPCRHR2FAAHPTGS1 | |
| SCHEMBL3404340 | 0.90 | PTGS2 (0.32) | PTGS1PTGS2 | |
| SCHEMBL3402745 | 0.90 | PTGS2 (0.32) | PTGS1PTGS2 | |
| SCHEMBL3402898 | 0.90 | PTGS2 (0.32) | PTGS1PTGS2 | |
| SCHEMBL15135361 | 0.88 | MAPT (0.34) | MAPTCRHBPCRHR2FAAHPTGS1 | |
| SCHEMBL396352 | 0.88 | MAPT (0.34) | MAPTCRHBPCRHR2FAAHPTGS1 | |
| SCHEMBL13001173 | 0.86 | MAPT (0.30) | MAPTCRHBPCRHR2FAAHPTGS1 | |
| SCHEMBL13000862 | 0.86 | MAPT (0.30) | MAPTCRHBPCRHR2FAAHPTGS1 | |
| SCHEMBL13000821 | 0.86 | MAPT (0.30) | MAPTCRHBPCRHR2FAAHPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311800-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2010-12-09 | — | — | US | disclosed |
| US-20100311800-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2010-12-09 | — | — | US | disclosed |
| EP-2250158-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | Nicox S.A. (FR) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009106470-A2 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | NICOX S.A. (FR) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311800-A1 | ANGIOTENSIN II RECEPTOR ANTAGONISTS | AGTR2, AGTR1, AGT | MAPT 4132/4885CRHBP 460/4885CRHR2 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.